[ad_1]
Synopsis
The therapy uses a specific hyper immunoglobulin — a purified and enriched preparation of coronavirus-neutralising antibodies in high concentration. The company says if the project, which is in the phase-2 trial stage, succeeds, the treatment will be provided free of cost to government hospitals.
The Chudgars, the billionaire founders of Ahmedabad-based Intas Pharmaceuticals, are a reclusive lot. The brothers — Binish, Nimish, and Urmish — are seldom seen in industry meetings and rarely appear in the media. But their affinity for risky bets and knack for deft execution are often the topic of boardroom chatter. Four years ago, amid scepticism, the company outbid marquee private-equity groups to sink over USD700 million and buy part of
BY
- FONT SIZE
AbcSmall
AbcMedium
AbcLarge
Sign in to read the full article
You’ve got this Prime Story as a Free Gift
₹399/month
Monthly
PLAN
Billed Amount ₹399
₹208/month
(Save 49%)
Yearly
PLAN
Billed Amount ₹2,499
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
₹150/month
(Save 63%)
2-Year
PLAN
Billed Amount ₹3,599
15
Days Trial
+Includes DocuBay and TimesPrime Membership.
Already a Member? Sign In now
Why ?
Sharp Insight-rich, Indepth stories across 20+ sectors
-
Access the exclusive Economic Times stories, Editorial and Expert opinion
-
Clean experience with
Minimal Ads -
Comment & Engage with ET Prime community -
Exclusive invites to Virtual Events with Industry Leaders -
A trusted team of Journalists & Analysts who can best filter signal from noise
[ad_2]
Source link
